Medication info
Candesartan Tablets 8 mg (Candesartan Cilexetil)

Candesartan Tablets 8 mg (Candesartan Cilexetil)

Prescription medicationTabletOral
Ingredient · strength
Candesartan Cilexetil›8mg / 1 tablet
Manufacturer / importer
Medica Korea Co., Ltd.
Appearance
Light pink tablet with a convex shape on both sides
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202001794 · Approved 2020.03.16 · Insurance code 646005370

Summary

Main use
Treatment of essential hypertension and heart failure with left ventricular systolic dysfunction
Who takes it
Adults · Children
Adult dose
This medicine should be taken at the same time each day, regardless of meals. 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: In patients at high risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of at least 2 weeks, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary.
Child dose
1. Essential hypertension 6) Pediatric patients: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. 2. Heart failure 3) Pediatric patients: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Ingredients

Manufacturer
Medica Korea Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure with left ventricular systolic dysfunction

  • Essential hypertension
  • heart failure
View approved original text

This medication effectively controls blood pressure in patients with essential hypertension. It is also used for patients with heart failure with impaired left ventricular function who require additional therapy to ACE inhibitors or who do not tolerate ACE inhibitors well. Therefore, it assists in the treatment of hypertension and certain heart failure patients.

How to take

Adult dose

This medicine should be taken at the same time each day, regardless of meals. 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: In patients at high risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of at least 2 weeks, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary.

Child dose

1. Essential hypertension 6) Pediatric patients: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. 2. Heart failure 3) Pediatric patients: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this drug or its components, pregnant or nursing women, patients with severe liver disease, and patients with hereditary angioedema should not use this medication. Elderly patients, those with hyperkalemia, liver disease, heart valve disease, and those with impaired kidney function should use this drug cautiously and require regular monitoring. Side effects such as dizziness, back pain, and upper respiratory infections may occur during treatment; in severe cases, symptoms such as hypotension, worsening kidney function, and hyperkalemia may appear, so caution is needed. Especially, heart failure patients or those with weak kidney function should regularly monitor serum potassium and creatinine levels to monitor their condition. This medication may interact with other antihypertensive drugs, diuretics, potassium supplements, etc., so it is essential to consult healthcare personnel. Women who are planning to become pregnant or may be pregnant should not take this medication, and it is also advisable to avoid use while breastfeeding. The safety of this medication has not been established for children and adolescents under 18 years of age, so its use is not recommended. Caution should be taken when driving or operating machinery, as dizziness may occur, and in cases of overdose, hypotension and dizziness may occur, requiring immediate medical attention. This medication should be stored out of reach of children and should not be transferred to other containers.

Side effects

  • Dizziness
  • back pain
  • respiratory infection
  • upper respiratory tract infection
  • pharyngitis
  • rhinitis
  • fatigue
  • peripheral edema
  • chest pain
  • headache
Show 80 more
  • bronchitis
  • cough
  • sinusitis
  • nausea
  • abdominal pain
  • diarrhea
  • vomiting
  • joint pain
  • proteinuria
  • asthenia
  • fever
  • sensory disturbance
  • dyspepsia
  • gastritis
  • tachycardia
  • palpitations
  • increased creatine kinase
  • hyperglycemia
  • hypertriglyceridemia
  • hyperuricemia
  • myalgia
  • epistaxis
  • anxiety
  • depression
  • drowsiness
  • dyspnea
  • rash
  • increased sweating
  • hematuria
  • leukopenia
  • neutropenia
  • agranulocytosis
  • hyperkalemia
  • hyponatremia
  • hypoglycemia
  • dizziness
  • headache
  • intestinal vascular edema
  • nausea
  • diarrhea
  • increased liver enzyme levels
  • hepatitis
  • elevated AST
  • elevated ALT
  • elevated γ-GTP
  • jaundice
  • rash
  • urticaria
  • pruritus
  • angioedema
  • myalgia
  • weakness
  • increased creatine kinase
  • elevated myoglobin in the blood
  • elevated myoglobin in urine
  • rhabdomyolysis
  • joint pain
  • myalgia
  • back pain
  • kidney function impairment
  • acute kidney failure
  • interstitial pneumonia
  • shock
  • syncope
  • loss of consciousness
  • paralysis
  • hypertonia
  • syncope
  • facial flushing
  • weight gain
  • facial edema
  • thirst
  • sleep disturbances
  • decreased libido
  • amnesia
  • loss of appetite
  • increased appetite
  • tinnitus
  • taste disturbance
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. The storage temperature should ideally be maintained between 1 to 30 degrees Celsius. This helps to preserve the medication's effectiveness and safety for a longer period.

Appearance and packaging

Appearance

Light pink tablet with a convex shape on both sides

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.